首页> 外文期刊>Oncology letters >Histone deacetylase inhibitors induce the expression of tumor suppressor genes Per1 and Per2 in human gastric cancer cells
【24h】

Histone deacetylase inhibitors induce the expression of tumor suppressor genes Per1 and Per2 in human gastric cancer cells

机译:组蛋白脱乙酰酶抑制剂诱导人胃癌细胞中肿瘤抑制基因Per1和per2的表达

获取原文
获取原文并翻译 | 示例
           

摘要

Period circadian regulator (Per)1 and Per2 genes are involved in the molecular mechanism of the circadian clock, and exhibit tumor suppressor properties. Several studies have reported a decreased expression of Per1, Per2 and Per3 genes in different types of cancer and cancer cell lines. Promoter methylation dowitregulates Perl, Per2 or Per3 expression in myeloid leukemia, breast, lung, and other cancer cells; whereas histone deacetylasc inhibitors (1-IDACi) upregulatc Perl or Per3 expression in certain cancer cell lines. However, the transcriptional regulation of Perl and Per2 in cancer cells by chromatin modifications is not fully understood. The present study aimed to determine whether HDACi regulate Per! and Per2 expression in gastric cancer cell lines, and to investigate changes in chromatin modifications in response to HDACi. Treatment of KATO III and NCI-N87 human gastric cancer cells with sodium butyrate (NaB) or Trichostatin A (TSA) induced Perl and Per2 mRNA expression in a dose-dependent manner. Chromatin immunoprecipitaion assays revealed that NaB and TSA decreased lysine 9 trimethylation on histone 113 (H3K9me3) at the Perl promoter. TSA, but not NaB increased H3K9 acetylation at the Per2 promoter. It was also observed that binding of Sp1 and Sp3 to the Peri promoter decreased following NaB treatment, whereas Sp1 binding increased at the Per2 promoter of NaB- and TSA-treated cells. In addition, Per1 promoter is not methylated in KATO III cells, while Per2 promoter was methylated, although NaB, TSA, and 5-Azacytidine do not change the methylated CpGs analyzed. In conclusion, HDACi induce Perl and Per2 expression, in part, through mechanisms involving chromatin remodeling at the proximal promoter of these genes; however, other indirect mechanisms triggered by these HDACi cannot be ruled out. These findings reveal a previously unappreciated regulatory pathway between silencing of Peri gene by H3K9me3 and upregulation of Per2 by HDACi in cancer cells.
机译:期间昼夜节律调节剂(PER)1和PER2基因参与昼夜节律时钟的分子机制,表现出肿瘤抑制性质。几项研究报告了不同类型的癌症和癌细胞系中Per1,Per2和Per3基因的表达减少。启动子甲基化Dowittegulates perl,per2或per3表达在髓性白血病,乳腺癌,肺等癌细胞中;虽然组蛋白Deacetylasc抑制剂(1-Idaci)upregulatc perl或per3在某些癌细胞系中的表达。然而,染色质修饰的Perl和Per2在癌细胞中的转录调节尚不完全理解。本研究旨在确定HDACI是否调节!胃癌细胞系中的均表达,并研究了HDACI响应染色质修饰的变化。用剂量依赖性方式将Kato III和NCI-N87人胃癌细胞与丁酸钠(NAB)或吡酰汀(TSA)诱导Perl和Per2 mRNA表达的治疗。染色质免疫沉淀素测定显示,Nab和TSA在Perl启动子上的组蛋白113(H3K9ME3)上降低了赖氨酸9的三甲基化。 TSA,但NAB在PER2启动子上增加H3K9乙酰化。还观察到,NAB处理后SP1和SP3与PERI启动子的结合降低,而NAB和TSA处理细胞的PER2启动子的SP1结合增加。另外,均本促进剂在Kato III细胞中不甲基化,而均为Nab,TSA和5-氮杂曲线的甲基化不改变分析的甲基化CpG。结论,HDACI诱导Perl和Per2表达,部分地通过涉及在这些基因的近端启动子处进行染色质重塑的机制;然而,不能排除这些HDACI触发的其他间接机制。这些发现揭示了H3K9ME3的PERI基因沉默与HDACI在癌细胞中的UpRegulation之间未被覆富的调节途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号